Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Biopsy
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Immunotherapy
Magnetic Resonance Imaging
Melanoma
/ immunology
Middle Aged
Neoplasm Metastasis
Positron-Emission Tomography
Prognosis
Programmed Cell Death 1 Receptor
/ immunology
Retrospective Studies
Transcriptome
Treatment Outcome
Young Adult
FDG-PET/CT
Immune checkpoint inhibitors
Metabolic tumor burden
Metastatic melanoma
Prognosis
Systemic inflammatory response
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
28
03
2019
accepted:
20
06
2019
pubmed:
28
7
2019
medline:
21
10
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy. This retrospective study included 55 patients from two institutions who underwent 18F-FDG PET/CT before anti-PD1. Parameters extracted were SUVmax, SUVmean, HISUV (SUV-based Heterogeneity Index), TMTV (total metabolic tumor volume), TLG (total lesion glycolysis), BLR (Bone marrow-to-Liver SUVmax ratio), and SLR (Spleen-to-Liver SUVmax ratio). Each parameter was dichotomized using the median as a threshold. Association with survival, best overall response (BOR), and transcriptomic analyses (NanoString assay) were evaluated using Cox prediction models, Wilcoxon tests, and Spearman's correlation, respectively. At 20.7 months median follow-up, 33 patients had responded, and 29 patients died. Median PFS and OS were 11.4 (95%CI 2.7-20.2) and 28.5 (95%CI 13.4-43.8) months. TMTV (>25cm Low tumor burden correlates with survival and objective response while hematopoietic tissue metabolism correlates inversely with survival. These biomarkers should be further evaluated for potential clinical application.
Identifiants
pubmed: 31346755
doi: 10.1007/s00259-019-04411-7
pii: 10.1007/s00259-019-04411-7
doi:
Substances chimiques
Biomarkers, Tumor
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2298-2310Subventions
Organisme : NCI NIH HHS
ID : UH2 CA218149
Pays : United States
Références
J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98
pubmed: 24194352
Nuklearmedizin. 2011;50(3):116-21
pubmed: 21246162
Wiley Interdiscip Rev Syst Biol Med. 2017 Mar;9(2):
pubmed: 27943646
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61
pubmed: 27251642
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Cell Mol Immunol. 2012 Jan;9(1):11-9
pubmed: 22020068
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Klin Onkol. 2017 Winter;30(Supplementum3):32-39
pubmed: 29239190
Eur J Cancer. 2016 Sep;65:33-42
pubmed: 27451022
World J Radiol. 2017 Feb 28;9(2):27-33
pubmed: 28298962
Cancer Immunol Immunother. 2019 Feb;68(2):297-303
pubmed: 30478475
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Oncoimmunology. 2019 Mar 6;8(5):e1574197
pubmed: 31069132
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Nucl Med. 2010 Oct;35(10):759-63
pubmed: 20838282
Melanoma Res. 2019 Jun;29(3):318-321
pubmed: 30557217
EJNMMI Res. 2018 Aug 16;8(1):82
pubmed: 30117062
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Med Hypotheses. 2018 Jul;116:111-113
pubmed: 29857892
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6
pubmed: 22308361
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Oncoimmunology. 2018 Feb 20;7(4):e1413520
pubmed: 29632731
Oncoimmunology. 2017 Dec 14;7(3):e1408750
pubmed: 29399415
Hematol Oncol Clin North Am. 2014 Jun;28(3):537-58
pubmed: 24880946
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
Clin Cancer Res. 2015 Dec 15;21(24):5453-9
pubmed: 26289067
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
J Nucl Med. 2014 Jun;55(6):898-904
pubmed: 24711649
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Clin Nucl Med. 2016 Jun;41(6):e266-73
pubmed: 27055144
J Nucl Med. 2018 Jan;59(1):15-24
pubmed: 28596157
Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1592-8
pubmed: 22801730
Adv Exp Med Biol. 2014;816:437-69
pubmed: 24818733
Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195
pubmed: 29855694
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Cancer Immunol Immunother. 2017 Apr;66(4):503-513
pubmed: 28108766
Cancer Cell. 2002 Oct;2(4):289-300
pubmed: 12398893
Eur Radiol. 2018 Apr;28(4):1761-1770
pubmed: 29086023
Eur J Cancer. 2018 Mar;91:136-144
pubmed: 29360605
Vaccines (Basel). 2016 Sep 09;4(3):
pubmed: 27618112
Eur J Nucl Med Mol Imaging. 2013 May;40(5):685-92
pubmed: 23232507
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791